scholarly journals Effect of PPAR-γ Agonist on Adiponectin Levels in the Metabolic Syndrome: Lessons From the High Fructose Fed Rat Model

2007 ◽  
Vol 20 (2) ◽  
pp. 206-210 ◽  
Author(s):  
Y SHARABI ◽  
M ORONHERMAN ◽  
Y KAMARI ◽  
I AVNI ◽  
E PELEG ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Rat Model ◽  
Ppar Γ ◽  
The Metabolic Syndrome ◽  
High Fructose

scholarly journals Amelioration of High Fructose Diet-Induced Insulin Resistance, Hyperuricemia, and Liver Oxidative Stress by Combined Use of Selective Agonists of PPAR-α and PPAR-γ in Rats

2020 ◽  
Vol 3 (2) ◽  
pp. 76-86
Author(s):  
Mahmoud M. Farag ◽  
Ehab H. Ashour ◽  
Wessam F. El-Hadidy
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Serum Insulin ◽  
Combined Treatment ◽  
Vehicle Group ◽  
Control Group ◽  
Peroxisome Proliferator ◽  
Ppar Γ ◽  
The Metabolic Syndrome ◽  
High Fructose

Background: The use of high-fructose (Fr) corn sweeteners and sucrose in manufactured food has markedly increased recently. This excessive Fr intake has been proposed in the etiology of the metabolic syndrome, which shows an increasing prevalence throughout the world. Objective: In this study, we questioned whether fenofibrate (FF), a peroxisome proliferator-activated receptor (PPAR)-α agonist, and pioglitazone (PG), a PPAR-γ agonist, might be effective in ameliorating the metabolic syndrome in a rat model. Materials and Methods: The metabolic syndrome was induced by feeding rats a high-Fr (60%) diet for 10 weeks. The rats were divided into 5 groups: control group, fed a normal rat chow; Fr + vehicle group; Fr + FF group; Fr + PG group; and Fr + (FF + PG) group (treated with both drugs). Drug or vehicle treatment was given daily for 6 weeks (from weeks 5 to 10). Thereafter, blood and liver samples were obtained for biochemical studies. Results: Rats fed a high-Fr diet developed hyperglycemia, hyperinsulinemia, hyperuricemia, hypertriglyceri­demia, and hypercholesterolemia, and had increased serum alanine aminotransferase, hepatic tumor necrosis factor-α, and malondialdehyde levels but decreases in both glutathione content and superoxide dismutase activity. Rat treatment with FF and/or PG attenuated these alterations. The improvement was greater with the combined treatment than with either drug alone, and normalization of insulin sensitivity was observed only in rats treated with the combination therapy. Conclusion: Acting on the 2 main PPAR subfamilies, the combination of FF and PG provides a more efficacious therapy for modulating the changes in serum insulin, uric acid, and lipids, as well as the accompanying hepatic inflammation and oxidative stress that characterize the Fr-induced metabolic syndrome.

scholarly journals Improvement of Cardiac Fibrosis Biomarkers through Inflammation Inhibition by Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Administration in Metabolic Syndrome Rat Model

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 1013
Author(s):  
Mifetika Lukitasari ◽  
Mohammad Saifur Rohman ◽  
Dwi Adi Nugroho ◽  
Nila Aisyah Wahyuni ◽  
Mukhamad Nur Kholis ◽  
...  
Keyword(s):  
Gene Expression ◽  
Metabolic Syndrome ◽  
Green Tea ◽  
Rat Model ◽  
Cardiac Fibrosis ◽  
Significant Risk ◽  
Green Coffee ◽  
The Metabolic Syndrome ◽  
Tnf Α ◽  
Tgf Β1

Background: Metabolic syndrome is a significant risk factor for cardiovascular diseases. Green tea and green coffee extracts, antioxidant and anti-inflammatory agents may participate in metabolic syndrome-induced cardiac fibrosis alleviation. However, the effect of combination of those extracts still needs exploration. Therefore, this study investigated the effect of green tea and decaffeinated light roasted green coffee extracts and their combination in metabolic syndrome-induced cardiac fibrosis rats. Methods: Metabolic syndrome rat model was i1nduced through high-fat high sucrose diets feeding for 8 weeks and injection of low dose streptozotocin at the 2nd week. The metabolic syndrome rats were divided into 4 experimental groups metabolic syndrome rats (MS); metabolic syndrome rats treated with 300 mg/ kg b.w green tea extract (GT); metabolic syndrome rats treated with 200 mg/ kg b.w decaffeinated light roasted green coffee extract (GC); metabolic syndrome rats treated with the combination of the two extracts (CE); and a normal control (NC) group was added. Angiotensin 2 level was analyzed by ELISA method. Gene expression of NF-κB, TNF-α, IL-6, Tgf-β1, Rac-1, and α-sma were analyzed by touchdown polymerase chain reaction methods. Results: Metabolic syndrome rats treated with green tea and decaffeinated light roasted green coffee significantly decreased angiotensin-2 serum level and cardiac inflammation and fibrosis gene expression level (NF-κB, TNF-α, IL-6, Tgf-β1, Rac-1, and α-sma). More significant alleviation was observed in the combination group. Conclusion: This study suggested that combination of green tea and decaffeinated light roasted green coffee extracts showed better improvement in metabolic syndrome-induced cardiac fibrosis rat model compared to that of single extract administration through inflammation inhibition

METFORMIN ADMINISTRATION TO A RAT MODEL OF THE METABOLIC SYNDROME

2004 ◽  
Vol 22 (Suppl. 1) ◽  
pp. S110
Author(s):  
C BN Ferreira ◽  
M LR Cesaretti ◽  
M Ginoza ◽  
M T Zaneila ◽  
A B Ribeiro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Rat Model ◽  
The Metabolic Syndrome

Evolution of Peroxisome Proliferator-Activated Receptor Agonists

2007 ◽  
Vol 41 (6) ◽  
pp. 973-983 ◽  
Author(s):  
Feng Chang ◽  
Linda A Jaber ◽  
Helen D Berlie ◽  
Mary Beth O'Connell
Keyword(s):  
Metabolic Syndrome ◽  
Insulin Sensitivity ◽  
Adverse Effects ◽  
Phase Ii ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Metabolism Regulation ◽  
Ppar Γ ◽  
The Metabolic Syndrome ◽  
Phase Ii And Iii

OBJECTIVE: To discuss the evolution of peroxisome proliferator-activated receptor (PPAR) agonists from single site to multiple subtype or partial agonists for the treatment of type 2 diabetes, dyslipidemia, obesity, and the metabolic syndrome. DATA SOURCES: Information was obtained from MEDLINE (1966-March 2007) using search terms peroxisome proliferator-activated receptor agonist, PPAR dual agonist, PPAR α/γ agonist, PPAR pan agonist, partial PPAR, and the specific compound names. Other sources included pharmaceutical companies, the Internet, and the American Diabetes Association 64th-66th Scientific Sessions abstract books. STUDY SELECTION AND DATA EXTRACTION: Animal data, abstracts, clinical trials, and review articles were reviewed and summarized. DATA SYNTHESIS: PPAR α, γ, and δ receptors play an important role in lipid metabolism, regulation of adipocyte proliferation and differentiation, and insulin sensitivity. The PPAR dual agonists were developed to combine the triglyceride lowering and high-density lipoprotein cholesterol elevation from the PPAR-α agonists (fibrates) with the insulin sensitivity improvement from the PPAR-γ agonists (thiazolidinediones). Although the dual agonists reduced hemoglobin A1C(A1C) and improved the lipid profile, adverse effects led to discontinued development. Currently, PPAR-γ agonists (GW501516 in Phase I trials), partial PPAR-γ agonists (metaglidasen in Phase II and III trials), and pan agonists (α, γ, δ netoglitazone in Phase II and III trials) with improved cell and tissue selectivity are undergoing investigation to address multiple aspects of the metabolic syndrome with a single medication. By decreasing both A1C and triglycerides, metaglidasen did improve multiple aspects of the metabolic syndrome with fewer adverse effects than compared with placebo. Metaglidasen is now being compared with pioglitazone. CONCLUSIONS: Influencing the various PPARs results in improved glucose, lipid, and weight management, with effects dependent on full or partial agonist activity at single or multiple receptors. Although the dual PPAR compounds have been associated with unacceptable toxicities, new PPAR agonist medications continue to be developed and investigated to discover a safe drug with benefits in multiple disease states.

scholarly journals Effect of PPAR-Γ agonist-rosiglitazone-on adiponectin level in the metabolic syndrome

2005 ◽  
Vol 18 (5) ◽  
pp. A204-A204 ◽  
Author(s):  
Y SHARABI ◽  
I AVNI ◽  
Y KAMARI ◽  
M ORONHERMAN ◽  
E PELEG ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Adiponectin Level ◽  
Ppar Γ ◽  
The Metabolic Syndrome

W09-P-027 A new transgenic rat model of hepaticsteatosis and the metabolic syndrome

2005 ◽  
Vol 6 (1) ◽  
pp. 46
Author(s):  
V. Zídek ◽  
V. Landa ◽  
P. Mlejnek ◽  
N. Qi ◽  
J. Wang ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Rat Model ◽  
Transgenic Rat ◽  
The Metabolic Syndrome ◽  
Transgenic Rat Model

scholarly journals Alterations in Neutrophil Production and Function at an Early Stage in the High-Fructose Rat Model of Metabolic Syndrome

2014 ◽  
Vol 27 (8) ◽  
pp. 1096-1104 ◽  
Author(s):  
M. Tagzirt ◽  
D. Corseaux ◽  
L. Pasquesoone ◽  
F. Mouquet ◽  
C. Roma-Lavisse ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Rat Model ◽  
Early Stage ◽  
High Fructose ◽  
And Function
Sign in / Sign up

Export Citation Format

Share Document